David Cordo, C.P.A., M.B.A.
Chief Financial Officer
David Cordo has been working in the life sciences industry since 1990. He held senior management positions in finance at Biogen Idec, and during his seven-year tenure was involved in the worldwide commercial launch of Avonex, the company’s first billion-dollar drug. Previously, Dr. Cordo was Treasurer of Millennium Pharmaceuticals where he led finance teams in the raising of an $800M follow-on equity offering and a $400M convertible debt offering. Since leaving Millennium, Mr. Cordo has been Interim Chief Financial Officer for Epizyme, Dicerna Pharmaceuticals, CoStim Pharmaceuticals, Mitobridge, Potenza Therapeutics, Semma Therapeutics, Metamark Genetics and Avila Therapeutics.
He is a certified public accountant (CPA) and received his M.B.A. from Nichols College and his B.S.B.A. from Stonehill College.